PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MyMD Pharmaceuticals

BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (Nasdaq: PMCB), a clinical-stage biotechnology company developing cellular therapies for can.

MyMD Pharmaceuticals Secures Strategic Investments

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) (“MyMD”) a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forw.

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

Femasys

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company's first investment in externally deve.

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the process of requesting a meeting with the U.S. Food and Drug Administration (FDA) for guidance on further development of the technology. The meeting is expected to occur during the first quarter of 2024. In.

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Company's common stock, par value $0.001 per share, at a price of $3.25 per share in cash, less any applicable withholding taxes and without interest. The tender offer expired one minute after 11:59 p.m. on June 9, 2023, and was funded entirely through the Company's cash on.

PharmaCyte Biotech Announces Final Results of Tender Offer

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest. The Company also announces that it has completed a private placement financing of convertible redeemable preferred stock and warrants from existing investors, raising gross proceeds of approximately $35 million in a private placement financing of convertib.

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

LAS VEGAS--( BUSINESS WIRE )--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box ® for potential development of cellular therapies for cancer, diabetes and malignant ascites, announced today that its Board of Directors has authorized a second share repurchase program to repurchase up to $10 million of PharmaCyte's outstanding common stock. This second share repurchase authorization is effective immediately for a two-year period. PharmaCyte expects to fund the program with its available cash. The Company enacted a similar program in June 2022.

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box® Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box®

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte and Iroquois have reached a settlement which includes appointing five new independent directors to PharmaCyte's reconstituted Board.

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the following statement in response to Iroquois Capital's filing of a preliminary consent statement to commence a consent solicitation in lieu of a stockholder meeting. Iroquois Capital is seeking the consent of the Company's shareholde

PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation

Reiterates its Belief that the Root Cause of the Company's Problems is an Insular and Dysfunctional Board Comprised of Chairman and CEO Kenneth Waggoner's Entrenched Management Team and Unqualified, Hand-Picked Appointees Expresses Disappointment in the Board's Failure to Negotiate a Resolution to the Ongoing Proxy Fight in Good Faith By Reneging on its Proposed Settlement Framework and Continual Moving of Goalposts Warns the Board Against Any Plans to Delay the 2022 Annual Meeting to Use the Company's Stock Buyback Program in a Self-Serving and Entrenching Manner Believes Significant Value Can Be Unlocked at the Company with a New Culture of Accountability Emanating from the Boardroom NEW YORK , July 28, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte", "PMCB" or the "Company") (NASDAQ:PMCB), with an aggregate ownership stake together with the other participants in its solicitation of approximately 7.2% of the Company's outstanding shares, today announced that it has filed preliminary consent materials with the SEC regarding its solicitation of written consents from stockholders in lieu of a stockholder meeting to reconstitute a majority of the PharmaCyte Board of Directors (the "Board") with its slate of highly qualified nominees. In the preliminary consent materials, Iroquois detailed its belief that PharmaCyte's insular and dysfunctional Board, comprised entirely of the Company's failing management team and Chairman and CEO Kenneth Waggoner's hand-picked appointees lacking other public company directorship or capital markets experience, is the root cause of the Company's severe destruction of stockholder value and loss of credibility with investors, continually shifting timelines and missed milestones with respect to its clinical development efforts, erratic investor communication practices, misaligned incentive structures and highly irregular and problematic governance structure.

Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has commenced the pilot phase of its two-phase pig study. The pig study is the last of several requirements PharmaCyte has complied with related to the requests from the U.S. Food and Drug Administration (FDA) to lift the cli

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has achieved positive interim results in its study to establish a malignant ascites mouse model which will form the basis for further testing of the effectiveness of its CypsCaps™ plus ifosfamide pancreatic cancer therapy for

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

LAS VEGAS--(BUSINESS WIRE)--Preliminary Financial Results for Fiscal Year 2022 are announced by PharmaCyte Biotech, Inc.

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

NEW YORK , July 11, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), announced that on Friday, July 8, 2022, that it had delivered a written consent to  PharmaCyte Biotech, Inc. ("PharmaCyte", "PMCB" or the "Company") (NASDAQ: PMCB) seeking the consent of stockholders to expand the size of PharmaCyte's Board of Directors by eight (8) members and to elect Iroquois' slate of eight (8) highly qualified director candidates in lieu of a stockholder meeting. Iroquois also announced that it has publicly delivered to the Company's stockholders a letter explaining Iroquois' rationale for accelerating its campaign to materially reconstitute the Board given its serious concerns with the Company's demonstrated efforts to delay the holding of the 2022 annual meeting of stockholders and frustrate the exercise of corporate democracy.

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

NEW YORK , July 5, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte", "PMCB" or the "Company") (NASDAQ:PMCB) with beneficial ownership of approximately 6.3% of the outstanding common stock of the Company, today provided the following statement in response to certain actions recently taken by the Company, which Iroquois believes are a thinly-veiled attempt to entrench the incumbent directors on the Company's Board of Directors (the "Board") ahead of an upcoming election contest for control of the Board at the 2022 annual meeting of stockholders (the "2022 Annual Meeting"). "Iroquois has been consistent in its view that change is needed at PharmaCyte to ensure improved accountability from what, in our opinion, is its dysfunctional Board and management that we believe is beholden to Kenneth L.

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the results of a study to determine whether a previous established quantitative real-time PCR (qRT-PCR) could be used as a quality control test for its CypCaps™ product candidate. The qRT-PCR was used to gain data from testing of syri

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

Believes Truly Independent Board Required to Increase Accountability Given PharmaCyte's Long History of Missed Milestones Highlights Severe Governance Deficiencies and Recent Half-Baked Efforts to Appease Stockholders Nominates Seven Experienced Highly Qualified Director Nominees NEW YORK , June 23, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte" or the "Company") (NASDAQ:PMCB) with beneficial ownership of approximately 6.1% of the outstanding common stock of the Company, today announced that it has nominated a slate of seven (7) highly qualified director candidates for election to the PharmaCyte Board of Directors at the Company's upcoming 2022 annual meeting of stockholders. Iroquois also announced that it has publicly delivered a letter to the Company's stockholders making clear the case for a significant reconstitution of the Board with professionals possessing the requisite skillsets, experience, drive and sense of accountability needed to turn the Company around.

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the following statement in response to the second letter issued by Iroquois Capital (Iroquois) on June 9, 2022: We Take Issue with Iroquois' Unfounded Statements On June 7, 2022, we issued a detailed letter to our shareholde

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will represent PharmaCyte at the 2022 BIO International Convention (BIO) being held at the San Diego Convention Center in San Diego, California, June 13-16. PharmaCyt

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

Believes the Company's Recently Announced Initiatives are a Reactionary and Transparent Attempt to Placate Stockholders by Conveniently Implementing a Few of Iroquois' Long-Standing Recommendations Without Addressing the Real Underlying Issues at the Company Questions the Company's Failure to Publicly Disclose the Material Terms of Executive Compensation Arrangements Recently Entered Into and How Such Arrangements Will Align Incentives Between the Company's Leadership and its Stockholders Identifies the Dysfunctional Board, Whose Members Have Been Hand-Picked by and Are Beholden to the Company's Chairman, Chief Executive Officer, President and General Counsel, Kenneth L. Waggoner, and its Dismal Corporate Governance Practices, as the Root Causes of the Company's Woes Renews Call for the Company to Actively Enlist Stockholder Participation in a Process to Materially Reconstitute the Board with Highly Qualified Candidates with the Requisite Skillsets, Experience, Drive and Sense of Accountability Needed to Turn the Company Around NEW YORK , June 9, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PMCB" or the "Company") (NASDAQ:PMCB) with beneficial ownership of approximately 5.8% of the outstanding common stock of the Company, today announced that it has delivered a letter to the Company's Board of Directors.

IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued the following letter to its shareholders in response to the concerns expressed by Iroquois Capital Management (Iroquois) in its letter to the PharmaCyte Board of Directors (Board) dated May 11, 2022, and announces additiona

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte has authorized a share repurchase program to repurchase up to $10 million of PharmaCyte's outstanding common stock.

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has initiated the first in a series of studies to test the ability of its pancreatic cancer therapy to treat malignant ascites. The initiation of this first study was made possible after PharmaCyte's successful production of a Master Cell Bank a

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

Expresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Value Amid Prolonged Product Development Efforts Despite the Company's Strong Cash Position Criticizes the Company's Dismal Efforts to Communicate with Shareholders Including its Failure to Hold Quarterly Conference Calls Questions the Board and Management's Alignment with Shareholders Given Minimal Stock Ownership and Failure to Purchase Shares in the Open Market Calls on the Company to Actively Enlist Shareholder Participation in a Process to Refresh a Majority of the Directors on the Board with Highly Qualified Candidates to Fill Gaps in the Existing Leadership's Skillset and Bring Fresh Perspectives and an Ownership Mentality to the Boardroom NEW YORK , May 11, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest shareholders of PharmaCyte Biotech, Inc. ("PMCB" or the "Company") (NASDAQ:PMCB) with beneficial ownership of approximately 5.1% of the outstanding common stock of the Company, today announced that it has delivered a letter to the Company's Board of Directors. The full text of the letter follows: May 11, 2022 PharmaCyte Biotech, Inc.23046 Avenida de la Carlota, Suite 600 Laguna Hills, California 92653Attn: Board of Directors Dear Members of the Board of Directors: Iroquois Capital Management, LLC ("Iroquois Capital," "us," or "we") is one of the largest stockholders of PharmaCyte Biotech, Inc. ("Pharmacyte" or the "Company"), with ownership of approximately 5.1% of the Company's outstanding shares.

News for PharmaCyte Biotech Stock (PMCB)